Point mutations in the isocitrate dehydrogenases IDH1 and IDH2 have been confirmed as oncogenic drivers in only 0.9%–3% of all cancers (Molenaar et al., 2018) (Figure S1A). This evidence concerns the gene IDH2 and cancer.